Gilenya Dosage/Direction for Use

Assessment Prior to Initiating Gilenya: Cardiac Evaluation: Obtain a cardiac evaluation in patients with certain preexisting conditions (see PRECAUTIONS).
Prior to starting treatment, determine whether patients are taking drugs that could slow heart rate or atrioventricular (AV) conduction [see DOSAGE & ADMINISTRATION and INTERACTIONS).
Complete Blood Count (CBC): Review results of a recent CBC (see PRECAUTIONS and INTERACTIONS).
Serum transaminases (ALT and AST) and Total Bilirubin Levels: Prior to starting treatment with GILENYA (i.e., within 6 months), obtain serum transaminases (ALT and AST) and total bilirubin levels (see PRECAUTIONS).
Prior Medications: If patients are taking antineoplastic, immunosuppressive, or immune-modulating therapies, or if there is a history of prior use of these drugs, consider possible unintended additive immunosuppressive effects before initiating treatment with Gilenya (see PRECAUTIONS and INTERACTIONS).
Vaccinations: Test patients for antibodies to varicella zoster virus (VZV) before initiating Gilenya; VZV vaccination of antibody-negative patients is recommended prior to commencing treatment with Gilenya (see PRECAUTIONS). It is recommended that pediatric patients if possible, complete all immunizations in accordance with current immunization guidelines prior to initiating Gilenya therapy.
Important Administration Instructions: Patients who initiate Gilenya and those who reinitiate treatment after discontinuation for longer than 14 days require first-dose monitoring. This monitoring is also recommended when the dose is increased in pediatric patients (see DOSAGE & ADMINISTRATION).
Gilenya capsules should always be swallowed intact, without opening them. Gilenya can be taken with or without food.
Recommended Dosage: In adults and pediatric patients 10 years of age and older weighing more than 40 kg, the recommended dosage of Gilenya is 0.5 mg orally once daily.
In pediatric patients 10 years of age and older weighing less than or equal to 40 kg, the recommended dosage of Gilenya is 0.25 mg orally once daily.
Fingolimod doses higher than 0.5 mg are associated with a greater incidence of adverse reactions without additional benefit.
First-Dose Monitoring: Initiation of Gilenya treatment results in a decrease in heart rate, for which monitoring is recommended (see PRECAUTIONS and Pharmacology under ACTIONS). Prior to dosing and at the end of the observation period, obtain an electrocardiogram (ECG) in all patients.
First 6-Hour Monitoring: Administer the first dose of Gilenya in a setting in which resources to appropriately manage symptomatic bradycardia are available. Monitor all patients for 6 hours after the first dose for signs and symptoms of bradycardia with hourly pulse and blood pressure measurement.
Additional Monitoring after 6-Hour Monitoring: Continue monitoring until the abnormality resolves if any of the following is present (even in the absence of symptoms) after 6 hours: The heart rate 6 hours postdose is less than 45 bpm in adults, less than 55 bpm in pediatric patients 12 years of age and older, or less than 60 bpm in pediatric patients 10 or 11 years of age; The heart rate 6 hours postdose is at the lowest value postdose suggesting that the maximum pharmacodynamic effect on the heart may not have occurred; The ECG 6 hours postdose shows new onset second degree or higher AV block.
If postdose symptomatic bradycardia occurs, initiate appropriate management, begin continuous ECG monitoring, and continue monitoring until the symptoms have resolved if no pharmacological treatment is required. If pharmacological treatment is required, continue monitoring overnight and repeat 6-hour monitoring after the second dose.
Overnight Monitoring: Continuous overnight ECG monitoring in a medical facility should be instituted: in patients that require pharmacologic intervention for symptomatic bradycardia. In these patients, the first-dose monitoring strategy should be repeated after the second dose of Gilenya; in patients with some preexisting heart and cerebrovascular conditions (see PRECAUTIONS); in patients with a prolonged QTc interval before dosing or during 6-hour observation, or at additional risk for QT prolongation, or on concurrent therapy with QT prolonging drugs with a known risk of torsades de pointes (see PRECAUTIONS and INTERACTIONS); in patients receiving concurrent therapy with drugs that slow heart rate or AV conduction (see INTERACTIONS).
Monitoring After Reinitiation of Therapy Following Discontinuation: When restarting Gilenya after discontinuation for more than 14 days after the first month of treatment, perform first-dose monitoring, because effects on heart rate and AV conduction may recur on reintroduction of Gilenya treatment (see DOSAGE & ADMINISTRATION). The same precautions (first-dose monitoring) as for initial dosing are applicable. Within the first 2 weeks of treatment, first-dose procedures are recommended after interruption of 1 day or more; during weeks 3 and 4 of treatment first-dose procedures are recommended after treatment interruption of more than 7 days.